Undecanoate 250mg/ml 10ml Vial by Dragon-Pharma

Usage

1. Allow the 10 ml vial to reach room temperature (15–25 °C) before use — warmer oil flows more freely through the draw needle, reducing aspiration effort and air bubble formation.
2. Swab the rubber stopper with a 70 % isopropyl alcohol wipe and allow it to dry fully before inserting the draw needle to maintain sterile technique across multiple-use sessions.
3. Draw the calculated dose using an 18–21 gauge needle; given the 250 mg/ml concentration, a 1000 mg dose requires exactly 4 ml — measure carefully using the syringe graduation marks.
4. Switch to a 21–23 gauge, 1–1.5 inch intramuscular needle for injection; the gluteal or ventrogluteal site is preferred for volumes of 2–4 ml to minimise local tissue discomfort from the oil depot.
5. Inject slowly (1 ml per 10 seconds) and aspirate briefly before injection to confirm intramuscular placement — slow delivery reduces depot pressure, limiting post-injection soreness caused by rapid oil infiltration.
6. Record the injection date, vial lot number, and serum testosterone trough results in a cycle log; this data guides interval optimisation based on actual pharmacokinetic response rather than population-average estimates.

Warnings

Frequently asked questions

What is the half-life of injectable Testosterone Undecanoate at 250 mg/ml?

The mean elimination half-life of injectable testosterone undecanoate is approximately 20 to 34 days, as reported in published clinical pharmacokinetic studies. This extended half-life results from the 11-carbon undecanoate ester, which slows esterase-mediated hydrolysis to free testosterone. At Dragon-Pharma's 250 mg/ml concentration, each millilitre delivers a depot that sustains measurable plasma testosterone levels for several weeks post-injection.

How does the release profile of Testosterone Undecanoate differ from shorter-ester testosterone injections?

Testosterone undecanoate produces a gradual rise to peak serum concentrations over approximately 7–14 days post-injection, followed by a slow decline over weeks — a fundamentally different profile from testosterone propionate, which peaks within 24–48 hours and clears in under 4 days. This extended, flatter release curve reduces peak-to-trough hormonal fluctuation, making it pharmacokinetically preferable for users who prioritise concentration stability over rapid onset.

What injection frequency is appropriate given the pharmacokinetics of Testosterone Undecanoate injection?

Based on the 20–34 day half-life, injection intervals of 10 to 14 weeks are used in clinical hypogonadism protocols; performance-focused users often apply 8–12 week intervals to maintain higher steady-state androgen levels. Because trough concentrations remain within the physiological range at week 10–12 when the protocol is established, frequent re-dosing is not required — a key pharmacokinetic advantage of the long-acting undecanoate ester at any concentration, including 250 mg/ml.

Is a standard insulin syringe suitable for drawing Dragon-Pharma Testosterone Undecanoate from the 10 ml vial?

Insulin syringes are not recommended for drawing oil-based injectables like Testosterone Undecanoate — their narrow gauge makes aspirating viscous oil impractical and risks syringe damage. A larger draw needle (18–21 gauge) should be used to pull the dose from the 10 ml multi-dose vial, followed by a switch to a standard intramuscular injection needle (21–23 gauge, 1–1.5 inch) for administration. The 10 ml vial format allows multiple draws when protocols require dose adjustments.

How should an opened 10 ml vial of Dragon-Pharma Testosterone Undecanoate 250 mg/ml be stored?

After the rubber stopper is first punctured, the vial should be stored upright at room temperature (15–25 °C), away from direct light and heat sources. Refrigeration is not required and may increase oil viscosity, making drawing more difficult. Multi-dose vials should be used within the period specified on the label — typically 28 days after first opening — and any vial showing particulate matter, cloudiness, or colour change must be discarded regardless of remaining volume. (2) angle_used

Manufacturer

Dragon-Pharma's quality assurance for Testosterone Undecanoate 250 mg/ml centres on a specific aspect that sets it apart from standard in-house testing regimes: systematic collaboration with independent third-party analytical laboratories for batch-level verification. Rather than relying exclusively on internal QC data, Dragon-Pharma routes representative samples from each finished lot of the 10 ml vials to accredited external facilities, where concentration is quantified by HPLC against certified testosterone reference standards and sterility is confirmed via LAL endotoxin assay — both conducted by personnel and instruments with no commercial interest in the outcome. This third-party verification model creates an externally auditable documentation chain: the results generated by independent labs are recorded alongside internal batch certificates, giving distributors and end users a second analytical authority to reference when assessing product authenticity. For a compound where concentration accuracy directly determines pharmacokinetic behaviour — the 20–34 day half-life of testosterone undecanoate is dose-dependent — the precision of the 250 mg/ml declaration is not a marketing specification but a clinically meaningful figure that Dragon-Pharma treats as independently verifiable rather than self-reported.